Israel Ischemic Heart Disease (IHD) Drugs Market is expected to be dominated by Therapeutic Class type through 2028

Israel Ischemic Heart Disease (IHD) Drugs Market is expected to be dominated by Therapeutic Class type through 2028

Rising incidence of cardiovascular diseases is expected to drive the growth of the Israel ischemic heart disease (IHD) drugs market during the forecast period, 2018-2028, According to TechSci Research report, “Israel Ischemic Heart Disease (IHD) Drugs Market - By Region, Forecast and Opportunities, 2018-2028”, the Israel ischemic heart disease (IHD) drugs market is expected to grow with an impressive CAGR during the forecast period 2018-2028. The rise in prevalence of chronic diseases and growing awareness among key market players, including manufacturers, who are involved in new drug production with high efficacy, acquisitions, expansions, and strategic collaborations, and recent developments show the growth of the ischemic heart disease (IHD) drugs market.

However, one of the main contributing factors to the increasing prevalence of ischemic heart diseases is the aging population. As people age, the risk of developing hypertension increases. In addition, rising consumer awareness regarding the benefits of scheduled administration of these drugs is driving the growth of the Israel ischemic heart disease (IHD) drugs market during the forecast period.

Additionally, lifestyle habits such as excessive alcohol consumption and smoking along with physical inactiveness are leading to the growth of the Israel ischemic heart disease (IHD) drugs market.

Browse over 30 market data Figures spread through 70 Pages and an in-depth TOC on "Israel Ischemic Heart Disease (IHD)Drugs Market"

The Israel ischemic heart disease (IHD) drugs market can be segmented by disease class, drug class, distribution channel, and region.

The Israel ischemic heart disease (IHD) drugs market can be segmented by disease class, drug class, and region. Based on disease class, the market can be segmented into angina pectoris and myocardial infarction. Based on disease class, the market can be bifurcated into angina pectoris and myocardial infarction. The angina pectoris segment occupied the largest ischemic heart disease drugs market share in 2018, as they are easily treatable by lifestyle changes. However, the myocardial infarction segment is anticipated to depict fastest growth during the forecast period.

Based on the drug class, the market can be classified into following categories, anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, ACE inhibitors, ARBs, vasodilators, and antithrombotic agents. The calcium channel blockers segment is expected to show an impressive growth during the forecast period due to new technology that lowers blood pressure with less side effects.

Major companies operating in the Israel ischemic heart disease (IHD) drugs market include:

• Pfizer Pharmaceuticals Israel Ltd
• MERCK SERONO LTD.
• GlaxoSmithKline Israel Ltd
• Bayer-Israel
• Novartis Pharma Israel Ltd
• Sanofi-Aventis Israel Ltd
• Eli Lilly Israel
• Actelion Pharmaceuticals Israel Ltd
• Bristol-Myers Squibb Israel Ltd.
• Roche Pharmaceuticals (Israel) Ltd

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The Israel ischemic heart disease (IHD) drugs market is expected to witness significant growth during the forecast period on account of growing number of research and development in ischemic heart diseases. The technological advancement supports the demand for ischemic heart disease (IHD) in Israel. Additionally, an increase in emergence of players developing new drugs to prevent from heart failure and heart stroke, is expected to create lucrative opportunities for the market growth in the next few years” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based global management consulting firm.

“Israel Ischemic Heart Disease (IHD) Drugs Market, Disease Class (Angina Pectoris, Myocardial Infarction), By Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, ACE Inhibitors, ARBs, Vasodilators, Antithrombotic Agents), By Region, Competition Forecast & Opportunities, 2028”, has evaluated the future growth potential of the Israel Ischemic Heart Disease (IHD) Drugs Market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in the Israel ischemic heart disease (IHD) drugs market.

Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com